Qualification of Drivers; Exemption Applications; Diabetes Mellitus, 30940-30942 [2017-13929]

Download as PDF 30940 Federal Register / Vol. 82, No. 126 / Monday, July 3, 2017 / Notices 49 CFR 391.41(b)(11) was adopted in 1970, with a revision in 1971 to allow drivers to be qualified under this standard while wearing a hearing aid, 35 FR 6458, 6463 (April 22, 1970) and 36 FR 12857 (July 3, 1971). The five individuals listed in this notice have requested renewal of their exemptions from the hearing standard in 49 CFR 391.41(b)(11), in accordance with FMCSA procedures. Accordingly, FMCSA has evaluated these applications for renewal on their merits and decided to extend each exemption for a renewable two-year period. sradovich on DSK3GMQ082PROD with NOTICES II. Request for Comments Interested parties or organizations possessing information that would otherwise show that any, or all, of these drivers are not currently achieving the statutory level of safety should immediately notify FMCSA. The Agency will evaluate any adverse evidence submitted and, if safety is being compromised or if continuation of the exemption would not be consistent with the goals and objectives of 49 U.S.C. 31136(e) and 31315, FMCSA will take immediate steps to revoke the exemption of a driver. III. Basis for Renewing Exemptions Under 49 U.S.C. 31315(b)(1), an exemption may be granted for no longer than two years from its approval date and may be renewed upon application. In accordance with 49 U.S.C. 31136(e) and 31315, each of the twelve applicants has satisfied the renewal conditions for obtaining an exemption from the hearing requirement (80 FR 57032; 80 FR 60747). In addition, for Commercial Driver’s License (CDL) holders, the Commercial Driver’s License Information System (CDLIS) and the Motor Carrier Management Information System (MCMIS) are searched for crash and violation data. For non-CDL holders, the Agency reviews the driving records from the State Driver’s Licensing Agency (SDLA). These factors provide an adequate basis for predicting each driver’s ability to continue to safely operate a CMV in interstate commerce. The five drivers in this notice remain in good standing with the Agency and have not exhibited any medical issues that would compromise their ability to safely operate a CMV during the previous two-year exemption period. FMCSA has concluded that renewing the exemptions for each of these applicants is likely to achieve a level of safety equal to that existing without the exemption. Therefore, FMCSA has decided to renew each exemption for a two-year period. In accordance with 49 VerDate Sep<11>2014 17:53 Jun 30, 2017 Jkt 241001 U.S.C. 31136(e) and 31315, each driver has received a renewed exemption. As of June 10, 2017, the following five drivers have satisfied the renewal conditions for obtaining an exemption from the hearing requirement in 49 CFR 391.41(b)(11), from driving CMVs in interstate commerce (78 FR 22708). DEPARTMENT OF TRANSPORTATION Thomas Carr (PA) Robert Knapp (WI) Keith Miller (PA) Jeffrey Webber (OK) Michael Wilkes (MA) AGENCY: The exemptions are extended subject to the following conditions: (1) Each driver must report any crashes or accidents as defined in 49 CFR 390.5; and (2) report all citations and convictions for disqualifying offenses under 49 CFR part 383 and 49 CFR 391 to FMCSA. In addition, the driver must also have a copy of the exemption when driving, for presentation to a duly authorized Federal, State, or local enforcement official. The driver is prohibited from operating a motorcoach or bus with passengers in interstate commerce. The exemption does not exempt the individual from meeting the applicable CDL testing requirements. Each exemption will be valid for two years unless rescinded earlier by FMCSA. The exemption will be rescinded if: (1) The person fails to comply with the terms and conditions of the exemption; (2) the exemption has resulted in a lower level of safety than was maintained before it was granted; or (3) continuation of the exemption would not be consistent with the goals and objectives of 49 U.S.C. 31136(e) and 31315. V. Conclusion Based upon its evaluation of the nine exemption applications, FMCSA renews the exemptions of the aforementioned drivers from the hearing requirement in 49 CFR 391.41 (b)(11). In accordance with 49 U.S.C. 31136(e) and 31315, each exemption will be valid for two years unless revoked earlier by FMCSA. Issued on: June 22, 2017. Larry W. Minor, Associate Administrator for Policy. [FR Doc. 2017–13931 Filed 6–30–17; 8:45 am] BILLING CODE 4910–EX–P Fmt 4703 Qualification of Drivers; Exemption Applications; Diabetes Mellitus FMCSA announces its decision to exempt 49 individuals from its rule prohibiting persons with insulin-treated diabetes mellitus (ITDM) from operating commercial motor vehicles (CMVs) in interstate commerce. The exemptions enable these individuals to operate CMVs in interstate commerce. DATES: The exemptions were effective on May 31, 2017. The exemptions expire on May 31, 2019. FOR FURTHER INFORMATION CONTACT: Ms. Christine A. Hydock, Chief, Medical Programs Division, (202) 366–4001, fmcsamedical@dot.gov, FMCSA, Department of Transportation, 1200 New Jersey Avenue SE., Room W64– 113, Washington, DC 20590–0001. Office hours are from 8:30 a.m. to 5 p.m. e.t., Monday through Friday, except Federal holidays. SUPPLEMENTARY INFORMATION: SUMMARY: IV. Conditions and Requirements Frm 00125 [FMCSA Docket No. FMCSA–2017–0031] Federal Motor Carrier Safety Administration (FMCSA), DOT. ACTION: Notice of final disposition. The drivers were included in FMCSA–2014–0384. The exemptions were effective on June 10, 2017, and will expire on June 10, 2019. PO 00000 Federal Motor Carrier Safety Administration Sfmt 4703 I. Electronic Access You may see all the comments online through the Federal Document Management System (FDMS) at: http:// www.regulations.gov. Docket: For access to the docket to read background documents or comments, go to http:// www.regulations.gov and/or Room W12–140 on the ground level of the West Building, 1200 New Jersey Avenue SE., Washington, DC, between 9 a.m. and 5 p.m., e.t., Monday through Friday, except Federal holidays. Privacy Act: In accordance with 5 U.S.C. 553(c), DOT solicits comments from the public to better inform its rulemaking process. DOT posts these comments, without edit, including any personal information the commenter provides, to www.regulations.gov, as described in the system of records notice (DOT/ALL–14 FDMS), which can be reviewed at www.dot.gov/privacy. II. Background On April 27, 2017, FMCSA published a notice of receipt of Federal diabetes exemption applications from 50 individuals and requested comments from the public (82 FR 19438). The E:\FR\FM\03JYN1.SGM 03JYN1 Federal Register / Vol. 82, No. 126 / Monday, July 3, 2017 / Notices public comment period closed on May 30, 2017, and two comments were received. FMCSA has evaluated the eligibility of the 50 applicants and determined that granting the exemptions to 49 of these individuals would achieve a level of safety equivalent to or greater than the level that would be achieved by complying with the current regulation 49 CFR 391.41(b)(3). sradovich on DSK3GMQ082PROD with NOTICES Diabetes Mellitus and Driving Experience of the Applicants The Agency established the current requirement for diabetes in 1970 because several risk studies indicated that drivers with diabetes had a higher rate of crash involvement than the general population. The diabetes rule provides that ‘‘A person is physically qualified to drive a commercial motor vehicle if that person has no established medical history or clinical diagnosis of diabetes mellitus currently requiring insulin for control’’ (49 CFR 391.41(b)(3)). FMCSA established its diabetes exemption program, based on the Agency’s July 2000 study entitled ‘‘A Report to Congress on the Feasibility of a Program to Qualify Individuals with Insulin-Treated Diabetes Mellitus to Operate in Interstate Commerce as Directed by the Transportation Act for the 21st Century.’’ The report concluded that a safe and practicable protocol to allow some drivers with ITDM to operate CMVs is feasible. The September 3, 2003 (68 FR 52441), Federal Register notice in conjunction with the November 8, 2005 (70 FR 67777), Federal Register notice provides the current protocol for allowing such drivers to operate CMVs in interstate commerce. These 50 applicants have had ITDM over a range of 1 to 28 years. These applicants report no severe hypoglycemic reactions resulting in loss of consciousness or seizure, requiring the assistance of another person, or resulting in impaired cognitive function that occurred without warning symptoms in the past 12 months and no recurrent (2 or more) severe hypoglycemic episodes in the past 5 years. In each case, an endocrinologist verified that the driver has demonstrated a willingness to properly monitor and manage his/her diabetes mellitus, received education related to diabetes management, and is on a stable insulin regimen. These drivers report no other disqualifying conditions, including diabetes-related complications. Each meets the vision requirement at 49 CFR 391.41(b)(10). VerDate Sep<11>2014 17:53 Jun 30, 2017 Jkt 241001 The qualifications and medical condition of each applicant were stated and discussed in detail in the April 27, 2017, Federal Register notice and they will not be repeated in this notice. III. Discussion of Comments FMCSA received two comments in this proceeding. Charles W. Smith, who is included in this docket, submitted a comment asking if more information was needed for his exemption. Mr. Smith had a complete application at the time he was published in the Federal Register for the 30-day comment period. Since no negative comments were received regarding his case, he was granted an exemption effective May 31, 2017. Robert E. Branigan, Jr., who is also included on this docket, requested a document stating he is now exempt from the diabetes standard. An exemption was granted and mailed to him on May 31, 2017. IV. Basis for Exemption Determination Under 49 U.S.C. 31136(e) and 31315, FMCSA may grant an exemption from the diabetes requirement in 49 CFR 391.41(b)(3) if the exemption is likely to achieve an equivalent or greater level of safety than would be achieved without the exemption. The exemption allows the applicants to operate CMVs in interstate commerce. To evaluate the effect of these exemptions on safety, FMCSA considered medical reports about the applicants’ ITDM and vision, and reviewed the treating endocrinologists’ medical opinion related to the ability of the driver to safely operate a CMV while using insulin. Consequently, FMCSA finds that in each case exempting these applicants from the diabetes requirement in 49 CFR 391.41(b)(3) is likely to achieve a level of safety equal to that existing without the exemption. V. Conditions and Requirements The terms and conditions of the exemption will be provided to the applicants in the exemption document and they include the following: (1) That each individual submit a quarterly monitoring checklist completed by the treating endocrinologist as well as an annual checklist with a comprehensive medical evaluation; (2) that each individual reports within 2 business days of occurrence, all episodes of severe hypoglycemia, significant complications, or inability to manage diabetes; also, any involvement in an accident or any other adverse event in a CMV or personal vehicle, whether or not it is related to an episode of hypoglycemia; (3) that each individual PO 00000 Frm 00126 Fmt 4703 Sfmt 4703 30941 provide a copy of the ophthalmologist’s or optometrist’s report to the medical examiner at the time of the annual medical examination; and (4) that each individual provide a copy of the annual medical certification to the employer for retention in the driver’s qualification file, or keep a copy in his/her driver’s qualification file if he/she is selfemployed. The driver must also have a copy of the certification when driving, for presentation to a duly authorized Federal, State, or local enforcement official. VI. Conclusion Based upon its evaluation of the 50 exemption applications, FMCSA exempts the following 49 drivers from the diabetes requirement in 49 CFR 391.41(b)(3): Ronald J. Boe (MN) Robert E. Branigan, Jr. (PA) Wayne P. Cashion (TN) Randall J. Claeys (OR) Ronald G. Dalle (NY) Vincenzo Dellisola (NY) Gary L.A. Driggers (GA) Daniel L. Fernberg (WI) Steven A. Grover (CO) Kenneth L. Hawthorne (MS) Matthew A. Huebner (IL) James C. Hylton (VA) Michael A. Jacobson (IA) David C. Jossi (ID) Randy J. Kean (KY) Edward T. Klauck (MO) Carl R. Knapp (WA) Robert E. Knox (OR) Oris Lormeus (NY) James V. Maiorana (NY) Jerry S. Malloy (OK) James E. Mann, Jr. (NC) Tremaine E. Mathews (TX) Archie D. McCracken (NC) William M. Nafus (PA) David S.E. Patton (AR) Andrew J. Peard (NE) Ronald C. Pennyman (GA) Matthew B. Phillips (IN) Larry P. Pruitt (NC) Jose L. Ramos (NM) Danny L. Russell (NH) Ronald M. Salas (CA) Roger W. Senff (WY) David M. Seswick (OH) Charles W. Smith (VA) Jeffery A. Stone (IN) William C. Suozzo (PA) Sean M. Sweeney (NJ) Thomas W. Szaloy (NM) John A. Tagtgren (MN) Michael E. Thompson (WA) John A. Wargo (WV) Michael E. Weideman (SD) Monty A. Weigum (ND) Zachary B.J. Weihart (WI) James M. Wenzel (MN) Steven G. Wilcox (CA) E:\FR\FM\03JYN1.SGM 03JYN1 30942 Federal Register / Vol. 82, No. 126 / Monday, July 3, 2017 / Notices Nathaniel D. Winston (VA) Gerald G. Blacklock (PA), who was included in the request for comments notice published on April 27, 2017 (82 FR 19438), ceased using insulin during the comment period. As a result, he no longer requires an exemption to operate in interstate commerce and was not issued one by the Agency. In accordance with 49 U.S.C. 31136(e) and 31315 each exemption is valid for two years unless revoked earlier by FMCSA. The exemption will be revoked if the following occurs: (1) The person fails to comply with the terms and conditions of the exemption; (2) the exemption has resulted in a lower level of safety than was maintained before it was granted; or (3) continuation of the exemption would not be consistent with the goals and objectives of 49 U.S.C. 31136(e) and 31315. If the exemption is still effective at the end of the 2-year period, the person may apply to FMCSA for a renewal under procedures in effect at that time. Issued on: June 22, 2017. Larry W. Minor, Associate Administrator for Policy. [FR Doc. 2017–13929 Filed 6–30–17; 8:45 am] BILLING CODE 4910–EX–P DEPARTMENT OF TRANSPORTATION Federal Railroad Administration [Docket Number FRA–2017–0056] sradovich on DSK3GMQ082PROD with NOTICES Notice of Application for Approval of Discontinuance or Modification of a Railroad Signal System Under part 235 of Title 49 of the Code of Federal Regulations (CFR) and 49 U.S.C. 20502(a), this document provides the public notice that on May 23, 2017, CSX Transportation (CSX) petitioned the Federal Railroad Administration (FRA) seeking approval for the discontinuance or modification of a signal system. FRA assigned the petition Docket Number FRA–2017–0056. Applicant: CSX Transportation, Mr. Harry C. Rhoades, Director PMO C&S, 500 Water Street, Speed Code J—350, Jacksonville, FL 32202. CSX seeks to modify the signal system between milepost (MP) QHE–0.00 to MP QHE–2.70, and MP QHX–0.00 to MP QHX–1.20, and MP QHW–0.00 to MP QHW–1.20, on the Baltimore Division, Philadelphia Subdivision, Philadelphia, PA. CSX proposes to discontinue cab signals; install electronic track circuits, frame communication circuits, Positive Train Control (PTC) compatible VerDate Sep<11>2014 17:53 Jun 30, 2017 Jkt 241001 microprocessor based vital logic controllers, and replace wayside signals. The reason CSX gives for the proposed modification is that it will be done in conjunction with other modifications to the signal system to prepare for PTC implementation. A copy of the petition, as well as any written communications concerning the petition, is available for review online at www.regulations.gov and in person at the U.S. Department of Transportation’s (DOT) Docket Operations Facility, 1200 New Jersey Avenue SE., W12–140, Washington, DC 20590. The Docket Operations Facility is open from 9 a.m. to 5 p.m., Monday through Friday, except Federal Holidays. Interested parties are invited to participate in these proceedings by submitting written views, data, or comments. FRA does not anticipate scheduling a public hearing in connection with these proceedings since the facts do not appear to warrant a hearing. If any interested parties desire an opportunity for oral comment and a public hearing, they should notify FRA, in writing, before the end of the comment period and specify the basis for their request. All communications concerning these proceedings should identify the appropriate docket number and may be submitted by any of the following methods: • Web site: http:// www.regulations.gov. Follow the online instructions for submitting comments. • Fax: 202–493–2251. • Mail: Docket Operations Facility, U.S. Department of Transportation, 1200 New Jersey Avenue SE., W12–140, Washington, DC 20590. • Hand Delivery: 1200 New Jersey Avenue SE., Room W12–140, Washington, DC 20590, between 9 a.m. and 5 p.m., Monday through Friday, except Federal Holidays. Communications received by August 17, 2017 will be considered by FRA before final action is taken. Comments received after that date will be considered if practicable. Anyone can search the electronic form of any written communications and comments received into any of our dockets by the name of the individual submitting the comment (or signing the document, if submitted on behalf of an association, business, labor union, etc.). Under U.S.C. 553(c), DOT solicits comments from the public to better inform its processes. DOT posts these comments, without edit, including any personal information the commenter provides, to www.regulations.gov, as described in the system of records notice (DOT/ALL–14 FDMS), which can PO 00000 Frm 00127 Fmt 4703 Sfmt 4703 be reviewed at https:// www.transportation.gov/privacy. See also https://www.regulations.gov/ privacyNotice for the privacy notice of regulations.gov. Issued in Washington, DC. Robert C. Lauby, Associate Administrator for Railroad Safety Chief Safety Officer. [FR Doc. 2017–13975 Filed 6–30–17; 8:45 am] BILLING CODE 4910–06–P DEPARTMENT OF TRANSPORTATION Intelligent Transportation Systems Program Advisory Committee; Notice of Meeting ITS Joint Program Office, Office of the Assistant Secretary for Research and Technology, U.S. Department of Transportation. ACTION: Notice. AGENCY: The Intelligent Transportation Systems (ITS) Program Advisory Committee (ITS PAC) will hold a meeting on July 18 & 19, 2017, from 8:30 a.m. to 3:00 p.m. (EDT) in the Doubletree Crystal City Hotel, 300 Army Navy Drive, Arlington, VA 22202. The ITS PAC, established under Section 5305 of Public Law 109–59, Safe, Accountable, Flexible, Efficient Transportation Equity Act: A Legacy for Users, August 10, 2005, and reestablished under Section 6007 of Public Law 114–94, Fixing America’s Surface Transportation (FAST) Act, December 4, 2015, was created to advise the Secretary of Transportation on all matters relating to the study, development, and implementation of intelligent transportation systems. Through its sponsor, the ITS Joint Program Office (JPO), the ITS PAC makes recommendations to the Secretary regarding ITS Program needs, objectives, plans, approaches, content, and progress. The following is a summary of the meeting tentative agenda: (1) Welcome, (2) Subcommittee Breakout Sessions and Updates to Committee, (3) Connected Vehicle Discussion, (4) Discussion of Potential Advice Memorandum Topics, (5) Summary and Adjourn. The meeting will be open to the public, but limited space will be available on a first-come, first-served basis. Members of the public who wish to present oral statements at the meeting must submit a request to ITSPAC@ dot.gov, not later than July 7, 2017. Questions about the agenda or written comments may be submitted by U.S. Mail to: U.S. Department of E:\FR\FM\03JYN1.SGM 03JYN1

Agencies

[Federal Register Volume 82, Number 126 (Monday, July 3, 2017)]
[Notices]
[Pages 30940-30942]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-13929]


-----------------------------------------------------------------------

DEPARTMENT OF TRANSPORTATION

Federal Motor Carrier Safety Administration

[FMCSA Docket No. FMCSA-2017-0031]


Qualification of Drivers; Exemption Applications; Diabetes 
Mellitus

AGENCY: Federal Motor Carrier Safety Administration (FMCSA), DOT.

ACTION: Notice of final disposition.

-----------------------------------------------------------------------

SUMMARY: FMCSA announces its decision to exempt 49 individuals from its 
rule prohibiting persons with insulin-treated diabetes mellitus (ITDM) 
from operating commercial motor vehicles (CMVs) in interstate commerce. 
The exemptions enable these individuals to operate CMVs in interstate 
commerce.

DATES: The exemptions were effective on May 31, 2017. The exemptions 
expire on May 31, 2019.

FOR FURTHER INFORMATION CONTACT: Ms. Christine A. Hydock, Chief, 
Medical Programs Division, (202) 366-4001, fmcsamedical@dot.gov, FMCSA, 
Department of Transportation, 1200 New Jersey Avenue SE., Room W64-113, 
Washington, DC 20590-0001. Office hours are from 8:30 a.m. to 5 p.m. 
e.t., Monday through Friday, except Federal holidays.

SUPPLEMENTARY INFORMATION: 

I. Electronic Access

    You may see all the comments online through the Federal Document 
Management System (FDMS) at: http://www.regulations.gov.
    Docket: For access to the docket to read background documents or 
comments, go to http://www.regulations.gov and/or Room W12-140 on the 
ground level of the West Building, 1200 New Jersey Avenue SE., 
Washington, DC, between 9 a.m. and 5 p.m., e.t., Monday through Friday, 
except Federal holidays.
    Privacy Act: In accordance with 5 U.S.C. 553(c), DOT solicits 
comments from the public to better inform its rulemaking process. DOT 
posts these comments, without edit, including any personal information 
the commenter provides, to www.regulations.gov, as described in the 
system of records notice (DOT/ALL-14 FDMS), which can be reviewed at 
www.dot.gov/privacy.

II. Background

    On April 27, 2017, FMCSA published a notice of receipt of Federal 
diabetes exemption applications from 50 individuals and requested 
comments from the public (82 FR 19438). The

[[Page 30941]]

public comment period closed on May 30, 2017, and two comments were 
received.
    FMCSA has evaluated the eligibility of the 50 applicants and 
determined that granting the exemptions to 49 of these individuals 
would achieve a level of safety equivalent to or greater than the level 
that would be achieved by complying with the current regulation 49 CFR 
391.41(b)(3).

Diabetes Mellitus and Driving Experience of the Applicants

    The Agency established the current requirement for diabetes in 1970 
because several risk studies indicated that drivers with diabetes had a 
higher rate of crash involvement than the general population. The 
diabetes rule provides that ``A person is physically qualified to drive 
a commercial motor vehicle if that person has no established medical 
history or clinical diagnosis of diabetes mellitus currently requiring 
insulin for control'' (49 CFR 391.41(b)(3)).
    FMCSA established its diabetes exemption program, based on the 
Agency's July 2000 study entitled ``A Report to Congress on the 
Feasibility of a Program to Qualify Individuals with Insulin-Treated 
Diabetes Mellitus to Operate in Interstate Commerce as Directed by the 
Transportation Act for the 21st Century.'' The report concluded that a 
safe and practicable protocol to allow some drivers with ITDM to 
operate CMVs is feasible. The September 3, 2003 (68 FR 52441), Federal 
Register notice in conjunction with the November 8, 2005 (70 FR 67777), 
Federal Register notice provides the current protocol for allowing such 
drivers to operate CMVs in interstate commerce.
    These 50 applicants have had ITDM over a range of 1 to 28 years. 
These applicants report no severe hypoglycemic reactions resulting in 
loss of consciousness or seizure, requiring the assistance of another 
person, or resulting in impaired cognitive function that occurred 
without warning symptoms in the past 12 months and no recurrent (2 or 
more) severe hypoglycemic episodes in the past 5 years. In each case, 
an endocrinologist verified that the driver has demonstrated a 
willingness to properly monitor and manage his/her diabetes mellitus, 
received education related to diabetes management, and is on a stable 
insulin regimen. These drivers report no other disqualifying 
conditions, including diabetes-related complications. Each meets the 
vision requirement at 49 CFR 391.41(b)(10).
    The qualifications and medical condition of each applicant were 
stated and discussed in detail in the April 27, 2017, Federal Register 
notice and they will not be repeated in this notice.

III. Discussion of Comments

    FMCSA received two comments in this proceeding. Charles W. Smith, 
who is included in this docket, submitted a comment asking if more 
information was needed for his exemption. Mr. Smith had a complete 
application at the time he was published in the Federal Register for 
the 30-day comment period. Since no negative comments were received 
regarding his case, he was granted an exemption effective May 31, 2017. 
Robert E. Branigan, Jr., who is also included on this docket, requested 
a document stating he is now exempt from the diabetes standard. An 
exemption was granted and mailed to him on May 31, 2017.

IV. Basis for Exemption Determination

    Under 49 U.S.C. 31136(e) and 31315, FMCSA may grant an exemption 
from the diabetes requirement in 49 CFR 391.41(b)(3) if the exemption 
is likely to achieve an equivalent or greater level of safety than 
would be achieved without the exemption. The exemption allows the 
applicants to operate CMVs in interstate commerce.
    To evaluate the effect of these exemptions on safety, FMCSA 
considered medical reports about the applicants' ITDM and vision, and 
reviewed the treating endocrinologists' medical opinion related to the 
ability of the driver to safely operate a CMV while using insulin.
    Consequently, FMCSA finds that in each case exempting these 
applicants from the diabetes requirement in 49 CFR 391.41(b)(3) is 
likely to achieve a level of safety equal to that existing without the 
exemption.

V. Conditions and Requirements

    The terms and conditions of the exemption will be provided to the 
applicants in the exemption document and they include the following: 
(1) That each individual submit a quarterly monitoring checklist 
completed by the treating endocrinologist as well as an annual 
checklist with a comprehensive medical evaluation; (2) that each 
individual reports within 2 business days of occurrence, all episodes 
of severe hypoglycemia, significant complications, or inability to 
manage diabetes; also, any involvement in an accident or any other 
adverse event in a CMV or personal vehicle, whether or not it is 
related to an episode of hypoglycemia; (3) that each individual provide 
a copy of the ophthalmologist's or optometrist's report to the medical 
examiner at the time of the annual medical examination; and (4) that 
each individual provide a copy of the annual medical certification to 
the employer for retention in the driver's qualification file, or keep 
a copy in his/her driver's qualification file if he/she is self-
employed. The driver must also have a copy of the certification when 
driving, for presentation to a duly authorized Federal, State, or local 
enforcement official.

VI. Conclusion

    Based upon its evaluation of the 50 exemption applications, FMCSA 
exempts the following 49 drivers from the diabetes requirement in 49 
CFR 391.41(b)(3):

Ronald J. Boe (MN)
Robert E. Branigan, Jr. (PA)
Wayne P. Cashion (TN)
Randall J. Claeys (OR)
Ronald G. Dalle (NY)
Vincenzo Dellisola (NY)
Gary L.A. Driggers (GA)
Daniel L. Fernberg (WI)
Steven A. Grover (CO)
Kenneth L. Hawthorne (MS)
Matthew A. Huebner (IL)
James C. Hylton (VA)
Michael A. Jacobson (IA)
David C. Jossi (ID)
Randy J. Kean (KY)
Edward T. Klauck (MO)
Carl R. Knapp (WA)
Robert E. Knox (OR)
Oris Lormeus (NY)
James V. Maiorana (NY)
Jerry S. Malloy (OK)
James E. Mann, Jr. (NC)
Tremaine E. Mathews (TX)
Archie D. McCracken (NC)
William M. Nafus (PA)
David S.E. Patton (AR)
Andrew J. Peard (NE)
Ronald C. Pennyman (GA)
Matthew B. Phillips (IN)
Larry P. Pruitt (NC)
Jose L. Ramos (NM)
Danny L. Russell (NH)
Ronald M. Salas (CA)
Roger W. Senff (WY)
David M. Seswick (OH)
Charles W. Smith (VA)
Jeffery A. Stone (IN)
William C. Suozzo (PA)
Sean M. Sweeney (NJ)
Thomas W. Szaloy (NM)
John A. Tagtgren (MN)
Michael E. Thompson (WA)
John A. Wargo (WV)
Michael E. Weideman (SD)
Monty A. Weigum (ND)
Zachary B.J. Weihart (WI)
James M. Wenzel (MN)
Steven G. Wilcox (CA)

[[Page 30942]]

Nathaniel D. Winston (VA)

    Gerald G. Blacklock (PA), who was included in the request for 
comments notice published on April 27, 2017 (82 FR 19438), ceased using 
insulin during the comment period. As a result, he no longer requires 
an exemption to operate in interstate commerce and was not issued one 
by the Agency.
    In accordance with 49 U.S.C. 31136(e) and 31315 each exemption is 
valid for two years unless revoked earlier by FMCSA. The exemption will 
be revoked if the following occurs: (1) The person fails to comply with 
the terms and conditions of the exemption; (2) the exemption has 
resulted in a lower level of safety than was maintained before it was 
granted; or (3) continuation of the exemption would not be consistent 
with the goals and objectives of 49 U.S.C. 31136(e) and 31315. If the 
exemption is still effective at the end of the 2-year period, the 
person may apply to FMCSA for a renewal under procedures in effect at 
that time.

    Issued on: June 22, 2017.
 Larry W. Minor,
Associate Administrator for Policy.
[FR Doc. 2017-13929 Filed 6-30-17; 8:45 am]
 BILLING CODE 4910-EX-P